EVIDENCE-BASED RETATRUTIDE RESOURCE

Every answer about
retatrutide,
in one place.

Dosages. Side effects. Clinical trial data. Real experiences. RetaGuide cuts through the noise so you can make informed decisions about the most powerful weight loss molecule ever studied.

28.7% avg weight loss in Phase 3
Triple agonist (GLP-1 + GIP + glucagon)
2026 FDA submission expected

What you'll find here

No vendor bias. No prescription sales. Just comprehensive, evidence-based information.

⚖

Dosing Protocols

Complete titration schedules from 1mg to 12mg. What to expect at each dose. When and how to escalate safely.

⚠

Side Effects

Every reported side effect mapped by frequency, severity, and dose level. From common GI symptoms to the new dysesthesia signal.

📊

Clinical Trial Tracker

Live tracking of TRIUMPH and TRANSCEND trial readouts. Phase 3 data broken down into what actually matters for patients.

❓

Every Question Answered

Retatrutide vs tirzepatide. Can you drink alcohol? What about exercise? Hair loss? We cover every question the community asks.

Built on trial data,
written for real people.

Medical journals are dense. Reddit threads are unreliable. Telehealth blogs have an agenda. RetaGuide sits in the middle: rigorous enough to cite, clear enough to understand.

✓ Every claim sourced to published trial data
✓ Updated within 48 hours of new readouts
✓ No vendor affiliations or prescription sales
✓ Community experiences curated and contextualized
TRIUMPH-4 28.7% weight loss at 68 weeks
TRANSCEND-T2D-1 Efficacy confirmed in Type 2 diabetes
Additional Phase 3 Results expected over the next year
FDA Submission NDA expected late 2026

The retatrutide era is starting.
Know what you're getting into.

Retatrutide isn't just another weight loss drug. It's the first triple-receptor agonist to reach Phase 3, with weight loss results that surpass everything before it. The information gap is real, and it's growing. RetaGuide exists to close it.